Vyteris Incorporated is a medical instrument and supply company involved in the development and production of electronically controlled transdermal drug delivery systems that deliver drugs through the skin without using needles. They are the maker of the first active drug delivery patch to receive market approval from the U.S. Food and Drug Administration. Vyteris was founded as a spin out of the Transdermal Systems unit of Becton Dickinson in November of 2000, and since that time they have received over 181 worldwide patents, most of which still have at least ten years remaining.
Nearly eight years after their founding, Vyteris is headquartered in Fair Lawn, New Jersey, in a building that provides the team with over 27,000 square feet of space for the research, development and manufacturing of their products. LidoSite, Vyteris’ proprietary active transdermal drug delivery technology, delivers drugs comfortably through the skin using low-level electrical energy. This smart-patch system delivers drug directly to the blood stream, avoiding metabolism by the liver and reducing the stomach and gastrointestinal upsets that can be associated with oral drug administration.
There are numerous potential applications for Vyteris’ active patch drug delivery technology in treating a variety of diseases. The company has tested and documented the potential benefits of the technology in various clinical applications. The LidoSite product has beneficial applications in physician offices, hospitals, and commercial diagnostic laboratories and home use, in the areas of rheumatoid arthritis, dermatology, and oncology. The LidoSite smart patch now has approval from the F.D.A. for the delivery of over 220 drugs and with further research and development the potential for additional opportunities could be right around the corner.
Let us hear your thoughts: Vyteris Inc. Message Board